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Introduction. Sentinel lymph node biopsy in prophylactic mastectomy is controversial. It avoids lymphadenectomy in occult
carcinoma but is associated with increased morbidity. Women with BRCA mutations have a higher incidence of occult carcinoma
and our objective was to assess the clinical utility of sentinel lymph node biopsy when these women undergo prophylactic
mastectomy. Materials and Methods. Seven-year retrospective consecutive case-series study of women, with a BRCA deleterious
mutation, admitted to prophylactic mastectomy, at our center. Breast MRI < 6 months before surgery was routine, unless
contraindicated. Results. Fifty-seven patients (43% BRCA1; 57% BRCA2) underwent 80 prophylactic mastectomies. 72% of patients
had had breast cancer treated before prophylactic mastectomy or synchronously to it. The occult carcinoma incidence was 5%, and
half of the cases were invasive. SLNB was performed in 19% of the prophylactic mastectomies; none of these had tumor invasion.
Womenwith invasive carcinomawhohadnot undergone sentinel lymphnode biopsywere followed closelywith axillary ultrasound.
The median follow-up was 37 months, with no local recurrence; 1 patient died of primary tumor systemic relapse. Conclusions.
Our data do not support this procedure for routine (in agreement with previous literature), in this high risk for occult carcinoma
population.
1. Introduction
Prophylacticmastectomies have becomemore frequent [1, 2],
and there are several possible reasons for this. These include
new predictive models, the identification of gene mutations
other than BRCA (e.g., PALB2, CHEK2, and others), the
increased diagnosis of high-risk lesions, and the so-called
“Angelina Jolie effect” [3–6].
In women with a BRCA1/2 deleterious mutation, con-
tralateral prophylactic mastectomy is expected to improve
all-cause mortality [7, 8]. Meanwhile, there is no evidence
of a survival benefit with bilateral prophylactic mastectomies
(either in BRCAmutation carriers or other high-risk women)
[9]. There is also no evidence of any benefit of proceeding to
sentinel lymph node biopsy in prophylactic mastectomy, nor
any evidence about how to proceed when occult carcinoma is
found during prophylacticmastectomy and axillary staging is
no longer possible.
Sentinel lymph node biopsy is considered to have min-
imal surgical risk and avoids axillary lymphadenectomy if
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an occult carcinoma is found [10, 11]. However, it is time-
consuming and expensive and may cause complications
including paresthesias, lymphedema, and arm motion lim-
itation (with estimated risks of 9%, 2–7%, and 4%, resp.)
[12–15]. With a low probability of occult carcinoma in pro-
phylactic breast surgery [16] and a low probability of lymph
node metastasis [17], sentinel lymph node biopsy has been
estimated to benefit only 2.8% of patients [18]. A recent meta-
analysis has recommended against the routine use of sentinel
lymph node biopsy [16]. A positive sentinel lymph node
biopsy in the absence of occult carcinoma has also been
described [17, 19–25], and crossover metastasis was a possible
explanation [16, 17, 21–24].
Considering the higher incidence of prophylacticmastec-
tomies and the present controversy on sentinel lymph node
biopsy in this type of surgery, our study adds to the literature
by specifically addressing this subject in a high risk for occult
carcinoma women, BRCA1/2mutation carriers, and to whom
preoperative breast magnetic resonance imaging (MRI) was
routine. Our objective was then to review the outcomes and
clinical utility of sentinel lymph node biopsy in prophylactic
mastectomy in a consecutive group of systematically evalu-
ated high risk for occult carcinoma women.
2. Materials and Methods
We performed a retrospective analysis of BRCA1/2 mutation
carriers who underwent at least 1 prophylactic mastectomy
at our center, between 2009 and 2015. All the patients had
previously been counseled at our center’s Breast Cancer Risk
Evaluation Clinic.
The study population descriptive analysis included age,
genetic diagnosis, breast cancer history (no personal history
of breast cancer, breast cancer treated in the past or a
synchronous to prophylactic mastectomy, histology, clinical
stage, and previous oncological treatments), surgery per-
formed, breast and axillary histological findings, and follow-
up.
All patients underwent breast MRI within 6 months
before prophylactic mastectomy, unless contraindicated.
Breast MRI was carefully reviewed by our Breast Cancer
Committee Radiologists, in order to exclude infraclinical
or contralateral carcinoma. Any prophylactic side doubtful
lesion would undergo biopsy or SLNB would be directly
indicated (according to the level of suspicion and the risks
of postulating surgery).
Prophylactic mastectomies were total or skin-sparing
(with or without nipple sparing) mastectomies, with or with-
out immediate reconstruction. A dual technique (technetium
99 sulfur colloid and patent blue dye) was used for sentinel
lymph node biopsy.
Both prophylactic mastectomy type of surgery and the
indication for SLNB were indicated by the Breast Cancer
Committee (including dedicated radiologists, medical oncol-
ogists, and surgeons).The choice of prophylactic mastectomy
type is beyond the scope of this work. The indication for
SLNB took into consideration the patient informed consent
after discussing the benefits and risks of alternative proce-
dures and the risk factors for occult carcinoma.
For pathological examination, the breast parenchymawas
entirely processed in 3-4mm slices and the sentinel lymph
node was microscopically evaluated in 2mm slices using
hematoxylin-eosin staining (according to our prophylactic
mastectomy and sentinel lymph node biopsy protocol).
During this research, all specimens were reviewed by 2
pathologists to confirm the histological findings.
To determine the clinical utility of sentinel lymph node
biopsy, the occult carcinoma and the sentinel lymph node
biopsy positivity rates were calculated. Patient and tumor
characteristics were analyzed to identify positive predictive
factors for occult carcinoma or sentinel lymph node biopsy
positivity. For follow-up outcomes, local recurrence and
mortality were analyzed. Our study protocol was multidisci-
plinary defined and accepted by our Institution Committee.
3. Results
From a total of 73 women (101 prophylactic mastectomies),
57 patients (80 prophylactic mastectomies) were confirmed
to be BRCA1/2 deleterious mutation carriers and were con-
sidered for further analysis (Figure 1).
MRI was performed within 6months before prophylactic
mastectomy in 82% (𝑛 = 47) of the patients. The remaining
patients either refused the examination, were allergic to the
MRI contrast agent, or had other MRI contraindications
(Table 1).
Half of the women (51%) had been treated with chemo-
therapy, radiotherapy, or hormonotherapy before undergoing
prophylactic mastectomy.These therapies were either neoad-
juvant treatment for breast cancer that was being operated
on simultaneously with the prophylactic mastectomy or
treatment for a previous breast cancer. Women who had
previously undergone surgery for breast cancer had amedian
time interval between breast cancer surgery and prophylactic
mastectomy of 90 months (interquartile range [IQR] 10–228
months). No locally advanced or metastatic breast cancer
was present at the time of prophylactic mastectomy. Two
patients underwent surgery for recurrent breast cancer at
the same time as their contralateral prophylactic mastectomy
(Supplementary Table 1).
The occult carcinoma rate was 5% (𝑛 = 4), and the occult
invasive carcinoma rate was 2.5% (𝑛 = 2). Occult carcinoma
occurred in 75% of patients with a personal history of breast
cancer and a BRCA1 pathogenic mutation, although this was
not a significant result because of the small number of cases.
Among the 4 patients with occult carcinoma, this was present
at a small volume of disease and there were no relevant
similitudes in the characteristics of breast cancer (if there was
a previous or synchronous breast cancer diagnosed before
surgery), radiological findings on the prophylactic side, or
occult carcinoma histological findings. During a median
follow-up of 30 months (IQR 25–55 months), no local or
distant recurrence was diagnosed (Table 2).
A sentinel lymph node biopsy was performed in 19% (𝑛 =
15) of the prophylacticmastectomies.Median number of SLN
removed per operated breast was 1 (1-2).
The sentinel lymph node was identified in all of the
cases, and none was positive for tumor cells. Nonsentinel
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Prophylactic
breast surgery
2009–2015
Synchronous
prophylactic and
therapeutic
mastectomies
24 women
(24 prophylactic
mastectomies)
Status after mastectomy
(breast cancer in the past)
10 women
(10 prophylactic mastectomies)
No history of
breast carcinoma
16 women
(32 prophylactic
mastectomies)
73 women
(101 prophylactic
mastectomies)
72% (n = 41) women with
breast cancer diagnosis
(previous or synchronous
with prophylactic
mastectomy)
60% (n = 48) prophylactic
mastectomies
28% (n = 16) women
with no breast
cancer diagnosis
40% (n = 32)
prophylactic
mastectomies
Positive for 
pathogenic BRCA
57 women
(80 mastectomies)
mutation
Status after conservative
surgery (breast cancer in the past)
7 women
(14 prophylactic mastectomies)(1)
Figure 1: Patients admitted to prophylactic breast surgery ((1) including prophylactic mastectomy of the remnant breast).
lymph nodes were not retrieved in any of the cases. In our
center, the rate of sentinel lymph node biopsy in prophylactic
mastectomy was at its highest in 2015 (71% of the cases). Two
women with occult invasive carcinoma had not undergone
sentinel lymph node biopsy during prophylactic mastectomy
and were managed with both axillary ultrasound and close
follow-up.
With no patients (𝑛 = 57) lost to follow-up, at amedian of
37months (14–57), 1 death had occurred because of a primary
tumor in the contralateral breast (a 45-mm, not otherwise
specified, poorly differentiated, triple-negative, invasive car-
cinoma) and systemic relapse. There were no breast or
axillary recurrence events (both prophylactic and therapeutic
sides).
4. Discussion
Sentinel lymph node biopsy is controversial in the prophylac-
tic mastectomy setting because of the expected advantage of
avoiding axillary lymphadenectomy versus the lownumber of
cases it will benefit [26]. Studies addressing this question have
included a heterogeneous population of high-risk women. In
addition to including only BRCA1/2mutation carriers, other
notable characteristics of our study included the facts that an
MRI evaluation before surgery is part of our standard proto-
col and that whole specimens of the breast parenchyma were
entirely processed and the slides reviewed to confirm histo-
logic findings. Our study population is the result of a system-
atized assessment by both a Breast Cancer Risk Evaluation
Clinic and a Breast Cancer Committee.
First of all, in what regards MRI, others have argued
against its routine use in prophylacticmastectomy, because of
its high cost and low sensitivity for the detection of occult car-
cinoma [22]. However, MRI is recommended for the surveil-
lance of BRCA1/2 mutation carriers [27, 28]; MRI has a high
negative predictive value for invasive carcinoma [29] and can
be useful for selecting women who do not need to undergo
4 International Journal of Breast Cancer
Table 1: Descriptive analysis of the prophylactic mastectomy population.
Patient characteristics Number of patients(𝑁 = 57) %
Age (years), median (IQR) 43.8 (37–51)
BRCA mutation
(i) BRCA1 25 43
(ii) BRCA2 32 57
MRI evaluation prior to surgery 47 82
Surgery description
Number of
mastectomies
(𝑁 = 80)
%
Breast: total mastectomy 100
(i) Type of prophylactic surgery
Total mastectomy 4 5
Skin (+/− nipple) sparing mastectomy 76 95
(ii) Type of reconstruction
Latissimus dorsi flap and definitive breast implant 54 68
Subpectoral breast implant or tissue expander 25 31
Transverse rectus abdominis muscle flap 1 1
Axilla
(i) Sentinel lymph node biopsy 15 19%
IQR: interquartile range.
sentinel lymph node biopsy (because occult carcinomas that
have not been identified using MRI have a lower probability
of lymph node metastasis) [30]. Our group reinforces the
importance ofMRI at a short interval before surgery, since all
our patients had a BRCA1/2 pathogenic mutation and, there-
fore, a higher risk both for occult and for interval carcinoma.
In fact, in spite of being a high-risk group, the occult carci-
noma incidence in our study (5%)was similar to that reported
by others (6.0% [3], 4.8% [10], and 1.76% [31]) and the same
can be concluded for our occult invasive carcinoma rate
(2.5% versus 2% [17], 1.2% [10, 31], and 0% [3]).
In what concerns the sentinel lymph node biopsy rate
(19%), it was lower than other reported rates (21.8% [31], 29%
[22], 66.7% [3], 74% [30], and 76.9% [17]). However, for the
follow-up described in our study, the patient outcome was
not affected by the decision to undergo sentinel lymph node
biopsy and the verified death was because of primary tumor
progression, with no local recurrence events.
For the evaluation of possible positive predictive factors,
this could not be accomplished, consideringwe foundnopos-
itive sentinel lymph nodes. In the literature, sentinel lymph
node biopsy positivity was associated with contralateral
breast cancer, especially if the disease was locally advanced
or inflammatory, and with a higher number of positive
lymph nodes [3, 16–18, 21–23, 25, 32]. Sentinel lymph node
biopsy positivity was also associated with lymphovascular
or skin/nipple involvement, higher histologic grades [21],
patients aged over 60 years, and lobular histology [26]. Of rel-
evance, in our group of patients there was no locally advanced
breast cancer case at the time of prophylactic mastectomy.
The decision to do not proceeding to lymphadenectomy
in patients with occult invasive cancerwithout sentinel lymph
node biopsy has been described by others [19, 31] and,
in our perspective, close follow-up (comprising an axillary
ultrasound) is an option which avoids overtreatment or
lymphadenectomy-associated morbidity.
The median number of lymph nodes removed from
operated breasts was 1 (range 1-2), which is in agreement with
the results of other studies (1.35 [10], 1.46 [25], and 2 [31]).This
assessment is important because a higher number of biopsied
lymph nodes reduce the false negative rate but also increase
morbidity.
Limitations of our study include its retrospective nature,
the short follow-up period, and the fact that we did not
analyze complications related to sentinel lymph node biopsy
(due to an underreport perception). Unfortunately, a high
level of evidence on this subject is hard to achieve.
Finally, regarding our findings and the results in the litera-
ture, we recommend that sentinel lymph node biopsy should
be offered to a selected group of patients, including women
with a synchronous or previous breast cancer diagnosis and
those who cannot be evaluated using MRI in the short
interval before surgery.
5. Conclusion
Our data and present evidence support that performing a
sentinel lymph node biopsy in selected patients, instead of
routine sentinel lymph node biopsy, is the better approach
for prophylactic mastectomy, including in women with a
deleterious mutation in BRCA1/2. Even if recent routine
preoperative breast MRI is probably the most important
strategy in the selection of these patients, other factors must
be considered.
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